Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Antiviral Activity of T-20 in HIV-1 Positive Adults
NCT00002228Phase 2Completed
- Sponsor
- Trimeris, Inc.
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of enfuvirtide in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by Trimeris, Inc. Primary endpoint: Safety at 7 weeks. Status: completed.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00002228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002228.